The shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) and TransEnterix, Inc. (NYSE:TRXC) were among the active stocks of the last trading sessions. Neos Therapeutics, Inc. (NASDAQ:NEOS) declined to -2.99% closing at the price of $2.6 whereas the shares of TransEnterix, Inc. (NYSE:TRXC) declined -3.8% with the decrease of -0.12 points closing at the price of $3.04. Neos Therapeutics, Inc. has currently decrease -67.09% in its stock over the period of 6-months while its rival TransEnterix, Inc. added 46.15% in the previous 6-months.
Now we have to analyze the facts that if the stocks were worthy off investors’ money? The facts to analyze here are risks, profitability, returns and price trends.
Returns and Profitability
Profitability and returns are the main reason of investment, the investors are looking for profits that they get and return they should expect over the period of time.
The first and foremost return that is considered while making an investment is the ROI or Return on Investment. The ROI is the ratio between the profit against the cost of investment. Currently the ROI of Neos Therapeutics, Inc. (NASDAQ:NEOS) is -83% while the ROI of TransEnterix, Inc. (NYSE:TRXC) is -30.5%. Another figure that is to be considered while analyzing the profitability of a share is its EBITDA margin, NEOS’s EBITDA Margin is -3.22 whereas TRXC’s is -15.45.
Both the profitability ratios suggest a mixed sentiment for Neos Therapeutics, Inc. (NASDAQ:NEOS) and TransEnterix, Inc. (NYSE:TRXC).
EPS & Surprise Factor
Neos Therapeutics, Inc. (NASDAQ:NEOS) reported $-0.52/share EPS for the previous quarter where analysts were predicting an EPS to be $-0.44/share Thus lagging the analyst Estimates with a Surprise Factor of -18.2 Percent. While, TransEnterix, Inc. (NYSE:TRXC) reported EPS of $-0.06/share in the last quarter. The analysts projected EPS of $-0.06/share depicting a Surprise of 0 Percent.
Taking a look at Earnings per Share, TransEnterix, Inc. tends to be beating the analyst estimates more than Neos Therapeutics, Inc.. so TRXC is more profitable than NEOS.
Technical Analysis of Neos Therapeutics, Inc. & TransEnterix, Inc.
Moving average convergence divergence (MACD) shows that Neos Therapeutics, Inc. (NASDAQ:NEOS) is on a PRICE RELATIVITY trend While TransEnterix, Inc. (NYSE:TRXC) is on PRICE RELATIVITY trend. The trend for the past 10-days shows that the Neos Therapeutics, Inc. was in BEARISH territory and TransEnterix, Inc. was in BULLISH territory.
NEOS’s current statistics gauge that the stock candle is BULLISH with HIGH volatility. While TRXC’s candle is NEUTRAL with HIGH.
EPS Growth Rate: NEOS’s 24.5% versus TRXC’s 0%
Another shareholder value can be analyzed through the EPS growth rate; the next 5 years EPS growth rate is predicted by the analysts after the analyzing the previous trends. The next 5 year EPS growth rate of Neos Therapeutics, Inc. (NASDAQ:NEOS) is predicted at 24.5% while TransEnterix, Inc. (NYSE:TRXC) stands at 0%. These numbers suggest that NEOS is more suitable investment in terms of EPS growth rate.
Financial Risk and Liquidity Concerns
The current ratio and the debt ratio are the two ratios that show the investor how quickly the company is able to payout its debt and how quickly it can cover its obligations. The current ratio of NEOS stands at 1.1 while TRXC is at 7.4 whereas the debt ratio of the prior is 0 while the debt ratio of the later is 0.11.
The values of the both ratios suggest that TRXC is more suitable investment when the liquidity and risk is the main concern.
While making an investment, another main factor to consider before investing is the analyst recommendation on the scale of 1 to 5 where 1 is strong buy, 2 is buy, 3 is hold, 4 is Sell and 5 is strong sell. Analyst recommend 2 for NEOS and 2.4 for TRXC which means NEOS has Buy rating whereas TRXC has Hold rating.
Another recommendation of analyst that is to be considered worthy is the price target. The mare price or price trend does not suggest the suitability of a stock. The price target set by analyst is also to be considered while investing as it suggests to what extent the stock will rise or fall in the near future. The price target set for NEOS is $16 which is 83.75% of its current price while TRXC has price target of 6.17 which is 50.73% of its current price.
Valuation is the process of determining the company’s worth for an investor, the valuation ratios give an insight to that worthiness.
NEOS currently has price to earning P/E ratio of 0 whereas TRXC has 0 while the forward P/E ratio for the prior stands at 0 and for the later it depicts the value of 0.
The price to Book P/B for NEOS is 0, Price to Sale is at 2.29 and for TRXC these ratios stand at 3.75 and 42.95.